0
Abstract: Slide Presentations |

FULMINANT COMMUNITY ACQUIRED ACINETOBACTER BAUMANNII PNEUMONIA AS A DISTINCT CLINICAL SYNDROME FREE TO VIEW

Wah S. Leung, MB, ChB*; Chung M. Chu, MBBS; Veronica L. Chan, MB, ChB; Judy Y. Lam, MBBS; Pak L. Ho, MD
Author and Funding Information

Department of Medicine, United Christian Hospital, Kowloon, Hong Kong PRC


Chest


Chest. 2005;128(4_MeetingAbstracts):149S. doi:10.1378/chest.128.4_MeetingAbstracts.149S
Text Size: A A A
Published online

Abstract

PURPOSE:  In previous uncontrolled studies, acinetobacter baumannii appears to be a rare but important cause of community acquired pneumonia (CAP-AB), that may run a fulminant course. We performed a retrospective study of CAP-AB to characterize its clinical course and outcome, by comparing it with a control group of patients with hospital acquired pneumonia caused by acinetobacter baumannii (HAP-AB).

METHODS:  This is a retrospective case-control study comparing CAP-AB with HAP-AB between July 2000 and December 2003. Clinical, laboratory, radiological and microbiological data were analyzed.

RESULTS:  There were 19 cases of CAP-AB (16 male and 3 female, mean age 72.6 ± 9.6 years) and 74 cases of HAP-AB during the 42-month study period. When compared to HAP-AB group, CAP-AB group has more ever smokers (84.3% vs. 55.4%, p = 0.031), more patients with COPD (63.2% vs. 29.7%, p = 0.014), and lower number of past hospitalization in the previous year (range: 0-0 vs. 0-6, p = 0.049). CAP-AB group had a higher prevalence of bacteremia (31.6% vs. 0%, p < 0.001). Strains causing HAP-AB were generally more resistant. There were higher frequencies of adult respiratory distress syndrome (ARDS) (84.2% vs. 17.6%, p < 0.001) and disseminated intravascular coagulation (DIC) (57.9% vs. 8.1%, p < 0.001) in the CAP-AB group. Moreover, the median survival was only 8 days in the CAP-AB group, versus 103 days in the HAP-AB (p=0.0026). Unexpectedly, early appropriate antibiotics in CAP-AB was not assoicated with better survival. Factors associated with higher mortality in the CAP-AB group included the presence of AB bacteremia (p = 0.040), platelet count < 120 x 10^9/L (p = 0.026), pH< 7.35 on presentation (p = 0.047) and presence of DIC (p = 0.004).

CONCLUSION:  CAP-AB appears to be a distinct clinical entity with a high incidence of bacteremia, ARDS, DIC and death, when compared to HAP-AB. Early appropriate antibiotics in CAP-AB was not assoicated with better survival.

CLINICAL IMPLICATIONS:  Further studies are needed to investigate the mechanism of the fulminant nature of CAP-AB.

DISCLOSURE:  Wah Leung, None.

Monday, October 31, 2005

2:30 PM - 4:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543